Zika virus–Dakar (DAK; Zika virus/A.africanus-tc/SEN/1984/41525-DAK) (GenBank accession no. KU955591) was used for the in vitro experiments in human keratinocytes, and Zika virus–French Polynesia (PF; Zika virus strain H/PF/2013) (GenBank accession no. KJ776791.2) was used for in vivo infection studies. Strains were provided by S. Weaver at the University of Texas Medical Branch and H.L. (coauthor of this study), respectively. Sendai virus strain Cantell was obtained from Charles River Laboratory. Zika virus stocks were prepared as described (55 (link)). All viruses were titered by focus-forming assay in Vero cells. Vero cells (CCL-81) were obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) and were verified as mycoplasma free by the LookOut Mycoplasma PCR Detection Kit (Sigma-Aldrich, St. Louis, MO, USA). In vitro Zika and Sendai virus infections were performed in serum-free media conditions for 1 hour, after which human keratinocyte medium with indicated treatment conditions was replenished.